Plain-English translation of NCT06071767 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a combination approach to HIV treatment that includes two vaccines (called ChAdOx1 and MVA), an immune-boosting medication called vesatolimod, and two broadly neutralizing antibodies. The goal is to help people with HIV who started treatment early in their infection learn to control the virus on their own, potentially reducing how much medication they need long-term.
Most people with HIV need to take antiretroviral drugs for life to keep the virus under control. This trial is exploring whether teaching the immune system to fight HIV better—through vaccination and antibody therapy—could help some patients maintain viral control with less medication or even without daily pills.
You would be randomly assigned to receive either the active treatment (vaccines, vesatolimod, and antibodies) or placebo injections while continuing your HIV medication for about 67 weeks. Then you would stop taking your HIV medication temporarily (for up to 24 weeks) while researchers monitor how well your immune system controls the virus on its own. Depending on how your virus behaves, you may restart medication and continue in the study for up to about 110 weeks total, with regular blood tests and clinic visits throughout.
AI-generated summary from trial data · Jun 29, 2026 · Not medical advice
United States